ONC vs REGN
BeOne Medicines Ltd. (ONC) and Regeneron Pharmaceuticals, Inc. (REGN) are both filed with the SEC under Pharmaceutical Preparations. ONC is 7.3× REGN's size by market cap ($550.6B against $75.9B); ONC trades at the higher fiscal-year P/E (1960.5× against 19.5×); REGN reports the higher net margin (31.4% against 5.4%); ONC grew sales faster over three years (+55.7% against +5.6%); and over the past year REGN returned +37.6% against ONC's +23.1%.
| ONC | REGN | |
|---|---|---|
| Last close | $366.73 | $794.19 |
| Market cap | $550.6B | $75.9B |
| P/E (FY) | 1960.5× | 19.5× |
| P/S | 103.0× | 5.3× |
| EV/EBITDA | 929.1× | 16.8× |
| Gross margin | 87.5% | — |
| Operating margin | 8.4% | 24.9% |
| Net margin | 5.4% | 31.4% |
| Return on equity | 7.5% | 14.9% |
| Sales growth (3y) | +55.7% | +5.6% |
| EPS growth (3y) | — | +2.8% |
| Dividend yield | — | 0.5% |
| 1-year return | +23.1% | +37.6% |
Screener snapshot — prices as of 2026-08-28. Each side's last close is the most recent session the snapshot holds for that company, which can be an earlier one, and its 1-year return is measured to that close. Market caps struck on 2026-08-27. Last close, market cap and the 1-year return are price figures; every other row is computed over the company's latest filed fiscal year — FY2025 (ended 2025-12-31) for both. — not published for this company. A ratio goes unpublished for more than one reason: a component the calculation needs is not on file, the filing does not tag the line it is read from, or the calculation is not defined on the filed basis — EV/EBITDA is not printed on non-positive EBITDA, and return on equity is not computed on a zero or negative equity base.
Who holds them, and who has traded them
| ONC | REGN | |
|---|---|---|
| Institutional holders (13F) | 280 | 1,384 |
| Insider buyers − sellers (180d) | -5 | -1 |
| Congressional trades disclosed (180d) | 0 | 2 |
| Executive-branch officials on file — trades disclosed (180d) | 0 | 7 |
Counts only. The congressional figures count transactions dated in the trailing 180 days and disclosed in STOCK Act periodic transaction reports; amounts are filed as ranges and are never summed. The executive-branch figures count the same window of transactions, and they are scoped to one roster. The officials OGE posts for direct download. Insider buyers − sellers counts distinct people filing open-market Form 4 purchases minus distinct people filing open-market sales over the trailing 180 days, capped at ±5.
ONC vs REGN: common questions
- Is ONC bigger than REGN?
- ONC carries the larger market cap — $550.6B against $75.9B, both struck on 2026-08-27.
- Which trades at a higher P/E, ONC or REGN?
- ONC, at a fiscal-year 1960.5× against 19.5× for REGN. Both are price ÷ latest full-year diluted earnings per share, not a trailing-twelve-month P/E.
- How have ONC and REGN performed over the past year?
- REGN returned +37.6% and ONC +23.1%, measured on the trailing calendar year to the last close.
- How many institutions hold ONC and REGN?
- 280 13F filers report a position in ONC and 1,384 in REGN, on the latest quarter in the panel.
- Are ONC and REGN in the same industry?
- Both are filed with the SEC under Pharmaceutical Preparations, which is the classification this pairing is built on.
ONC overview → · REGN overview → · ONC institutional ownership → · REGN institutional ownership → · Congress and REGN → · Executive branch and REGN →
More in Pharmaceutical Preparations: ABBV vs ABT · ABBV vs ONC · ABBV vs REGN · ABBV vs TEVA
Stock comparisons lists every pair this site publishes.
Source: SPZCO — https://spzco.com/vs/onc-vs-regn